The Factors That May Predict Response to Rituximab Therapy in Recurrent Focal Segmental Glomerulosclerosis: A Systematic Review
Recurrence of FSGS occurs in 30–40% of allografts. Therapies for recurrence are not well established. We retrieved all published reports depicting kidney transplant recipients with focal segmental glomerulosclerosis (FSGS) recurrence, treated with rituximab, to determine factors associated with trea...
Saved in:
Main Authors: | Carlos E. Araya, Vikas R. Dharnidharka |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2011-01-01
|
Series: | Journal of Transplantation |
Online Access: | http://dx.doi.org/10.1155/2011/374213 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Recurrent Focal Segmental Glomerulosclerosis: A Discrete Clinical Entity
by: Elena Torban, et al.
Published: (2012-01-01) -
Focal Segmental Glomerulosclerosis in Waldenström’s Macroglobulinemia
by: Akshee Batra, et al.
Published: (2020-01-01) -
Interferon Induced Focal Segmental Glomerulosclerosis
by: Yusuf Kayar, et al.
Published: (2016-01-01) -
Collapsing Focal Segmental Glomerulosclerosis in a Patient with Acute Malaria
by: Najamus Sehar, et al.
Published: (2015-01-01) -
Preoperative Low-Density Lipoprotein Apheresis for Preventing Recurrence of Focal Segmental Glomerulosclerosis after Kidney Transplantation
by: Akihito Sannomiya, et al.
Published: (2018-01-01)